Tag Archives: JAMA Oncology

Clinical Data for World’s First Truly Non-Invasive Prostate Cancer Test Published in JAMA Oncology

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exosome Diagnostics, Inc., a developer of revolutionary biofluid-based molecular diagnostics, announced the recent JAMA Oncology publication of a prospective clinical study for the company’s novel urine-based prostate cancer liquid biopsy test, ExoDxTM Prostate (IntelliScore). Topline results from the ...

Read More »